Streptomyces I06a - 00625 With S12a Secondary Metabolites Of Separation And Purification, Structure Identification

Pesudomonas aeruginosa (PA) is an opportunistic pathogenic bacteria, in clinic, often cause bacteremia, pneumonia, urinary tract infections and other infective diseases. Antibiotic misuse or abuse led to serious drug-resistance and multdrug-resistance. Multidrug-resistant (MDR) Pesudomonas aeruginosa often have active efflux system which could efflux variety of substances. Due to low outer membrane permeability, Pesudomonas aeruginosa decreased susceptibility to most antibiotics in clinic. So it is urgently needed to discover new drugs against Pesudomonas aeruginosa.The most of secreted proteins are exported by Sec translocase (Secretory pathway). SecA ATPase is preprotein translocase nanomotor that undergo membrane insertion and deinsertion to drive preprotein across the bacterial inner membrane, and is indispensable to bacteria. It should be presumed that SecA ATPase can be used as an ideal target for inhibiting bacteria.Streptomyces I06A-00625is screened by inhibitors screening model targeting to Pesudomonas aeruginosa SecA ATPase. And its metabolites have the activity for inhibiting the fungi and Pesudomonas aeruginosa. Macroporous adsorptive resins, Sephadex LH-20, HPLC and other column chromatographies were used to isolate and purify those compounds with the anti-microbial activity. After structural identification, one known compound, toyocamycin, was obtained. Three known polyene macrolide antibiotics, Tetramycin A, Tetramycin B and Tetrin A, were also isolated as fungicide.We also isolate and purify the secondary metabolites produced by Streptomyces S12A. Purified by several chromatographies, One known compound, cycloheximide was obtained, which has inhibitory activity against Magnaporth grisea.